DOCSLIB.ORG

ATLAS LINK Group Contents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ATLAS LINK Group Contents Contents ATLAS LINK Group 01 FERTILITY HCG Pregnancy Test Kits 03 LH Ovulation Test Kits 04 FSH Menopause Urine Test Kits 05 EUGENICS TORCH IgM and TORCH IgG Rapid Screening Test 06 INFECTIOUS DISEASE Hepatitis-B Surface Antigen Rapid Test 07 One Step HCV (Hepatitis C) Tests 08 One Step HIV Rapid Test Kits 09 One Step HIV / HBsAg / HCV Serum Test Panel 10 Other Hepatitis Rapid Test Kits 11 One Step NGH (Gonorrhea) Tests 12 One Step TP (Anti-Syphilis) Rapid Test Kits 12 One Step Chlam (Chlamydia) Tests 13 Dengue Rapid Test Kits 14 Malaria Rapid Test Kits 15 ATLAS LINK Group Tuberculosis (TB) Antibody Rapid Test 16 Mycoplasma Pneumonia (MP) Antibody Test 16 is a manufacturer of Various Types of In-Vitro diagnostics test kits, established Helicobacter pylori (H. pylori) Rapid Test Kits 17 sales in 1996 and registered manufacturer in China from 2004 to now. Strep A Antigen Rapid Test 18 the newly developed GMP plant under 1500M2 and 3000M2 stock for material and finished products, our manufacturing process strictly follows TUMOR MARKER the guidelines of ISO13485 ,with high quality material combined and R&D One-Step FOB (Fecal Occult Blood) Test 19 Alpha-fetoprotein (AFP) Rapid Test 20 research in Canada, most of our diagnostic products carrying CE approved. HEALTH MONITORING The production ability per month can meet ten million strips or 5 millions Prostate-Specific Antigen (PSA) Rapid Test 20 cassette, our sales have been covered more than 100 countries and area. Carcinoma Embryonic Antigen (CEA) Rapid Test 20 Myocardial infarction Rapid Test Kits 21 With in-house graphic design department, Our Own brand "Nova test" Saliva Alcohol Test Strip 22 becomes famous brand in the diagnostic market around the world, we can Micro-Albumin Urine Rapid Test 22 also offer quality services on our OEM packaging such as private labeling for DRUGS OF ABUSE complete line of the products. One Step Drugs of abuse Test 23 We, at Atlas link, Group are committed to supply diagnostics Tests Kits URINE REAGENT STRIPS to make diagnosis of various types of diseases simpler, faster and more Urine Reagent Strips 25 affordable world wide. ELISA 26 Our mission is to provide quality products that meet each customer's specific requirements in a timely manner with competitive prices. PRODUCTION Ordering Information 29 BASE IN CHINA 2 01 FERTILITY HCG Pregnancy Test Kits One Step Cassette Style HCG (human chorionic gonadotropin) Urine Pregnancy Test is a highly sensitive test kit for the determination of HCG in urine (and serum) specimens. This test kit is used to obtain a visual, qualitative result for early detection of pregnancy. After getting the CE certifi cate, our HCG test kits are widely sold to EU market. Features 1. An easy to use pregnancy test. No additional instrument or reagent is needed. 2. Detect within one week of pregnancy; 3. Accuracy: 99.9% Sensitivity: 10mIu/ml, or regular 25 mIU/ml. 4. Designed for both professional and home users. 5. Single package are available for the OTC market. Test Procedures 换吸管 Strip Cassette Midstream 1 1 1 4 drops 2 5min 2 5min 2 5min 3 3 3 Positive Positive Positive Negative Negative Negative Ordering information CAT. NO. Description Method Packing Specimen HCG 112 HCG Urine Strip GICA* 100 Tests/Box; 48 Boxes/Carton Urine HCG 113 HCG Urine Cassette GICA* 25 Tests/Box; 40 Boxes/Carton Urine HCG 113B HCG Urine Cassette (Box) GICA* 25 Tests/Box; 40 Boxes/Carton Urine HCG 114 HCG Urine Midstream GICA* 1 Test/Box; 360 Boxes/Carton Urine HCG 115 HCG U/S Combo Strip GICA* 100 Tests/Box; 48 Boxes/Carton Urine/Serum HCG 116 HCG U/S Combo Cassette GICA* 25 Tests/Box; 40 Boxes/Carton Urine/Serum * GICA: Lateral Flow Gold Immunochromatographic Assay; ** Carton Outer Size: 52*45*36CM. Gross weight about 14-15.5 KG/Carton. 02 03 FERTILITY FERTILITY LH Ovulation Test Kits One Step LH Ovulation Urine Test is a qualitative test that can predict when there is a LH surge, and in turn when a woman is likely to ovulate. These test kits can be used in monitoring the ovulation cycle for couples trying to conceive. FSH Menopause Urine Test Kits The FSH (human Follicular Stimulating Hormone) test results are of great clinical value to the diagnosis of many Features problems related with reproductive activities. One Step FSH Urine Test is a qualitative test kit for the determination of 1. Detect LH surge 24-48 hours before the release of fertile egg; FSH concentration in urine specimens, and in turn helps the testee to get prepared both physically and mentally for the 2. 99.5% accurate results in less than 5 minutes. syndromes come along with menopause. Visual and qualitative test results can be read visually without any instrumental 3. High Sensitivity: 15mIU/ml. help. 4. Designed for both professional and home users. 5. Single package with CE0123 mark are available for the OTC market. Features 6. Seven tests are recommended for one menstrual cycles. 1. An easy to use FSH test. No additional instrument or reagent is needed; 2. High sensitivity :25MIU/ML and accuracy: 99.47%; Test Procedures 换吸管 3. Designed for professional and home users; Strip Cassette Midstream 4. Each test is enclosed in a moisture proof aluminum pouch with a Silicon Gel for long time storage. 1 1 1 Test Procedures Strip Cassette 换吸管 Midstream 4 drops 1 1 1 2 5min 2 10min 2 5min 3 Positive 3 3 4 drops Positive Positive 2 5min 2 10min 2 5min Negative Negative 3 Positive 3 3 Negative Positive Positive Negative Negative Negative Negative Negative Negative Result refer to insert Ordering information Ordering information CAT. NO. Description Method Packing Specimen CAT. NO. Description Method Packing Specimen LH 131 LH Urine Strip GICA 100 Tests/Box; 48 Boxes/Carton Urine FSH 141 FSH Urine Strip GICA 100 Tests/Box; 48 Boxes/Carton Urine LH 132 LH Urine Cassette GICA 25 Tests/Box; 40 Boxes/Carton Urine FSH 142 FSH Urine Cassette GICA 25 Tests/Box; 40 Boxes/Carton Urine LH 133 LH Urine Midstream GICA 1 test/pouch; 1200 PCS/Carton Urine FSH 143 FSH Urine Midstream GICA 1 test/pouch; 1200 PCS/Carton Urine * GICA: Lateral Flow Gold Immunochromatographic Assay; * GICA: Lateral Flow Gold Immunochromatographic Assay; ** Carton Outer Size: 52*45*36CM. Gross weight about 14-15.5 KG/Carton. ** Carton Outer Size: 52*45*36CM. Gross weight about 14-15.5 KG/Carton. 04 05 EUGENICS INFECTIOUS DISEASE Hepatitis-B Surface Antigen Rapid Test TORCH IgM and TORCH IgG Rapid Screening Test Various test kits are available for Hepatitis B virus (HBV) infection, and they are widely used in the clinical diagnosis, treatment and prognosis of hepatitis B disease. The presence of HBsAg indicates recent infection, and if it persists for more than 6 months, The acronym TORCH was introduced to highlight a group of viral diseases which affect the fetus and newborn, namely the patient may become a chronic carrier. The development of serological assays to detect hepatitis B surface antigen (HBsAg) Toxoplasma gondii (TOXO), rubella virus (RV), cytomegalovirus (CMV), and herpes simplex viruses (HSV). These diseases often has played a major role in the diagnosis of hepatitis B virus (HBV) infection. lead to a similar clinical picture which includes one or more of the following clinical signs: low birth weight, prematurity, purpura, jaundice, anemia, microcephaly, hydrocephaly, cerebral calcifi cation, chorioretinitis, cataracts, microphthalmia, hearing One Step Hepatitis B antigen rapid test kits are based on the principle of sandwich immunoassay, for qualitative determination impairment, mental retardation, autism and pneumonitis. The early diagnosis of ToRCH infection is very important to avoid the of HBsAg in serum/plasma specimens symptoms and lesions. Features TORCH IgM test panel and TORCH IgG test panel are rapid lateral fl ow test designed for the qualitative detection of the IgM and IgG antibodies to the following viruses in human serum/plasma specimens: Toxoplasmosis (TOXO), Cytomegalovirus (CMV), 1. Takes less than 10-20 minutes to be sure; Rubella Virus (RV), Herpes Simplex Virus Type 1 (HSV-1) and Herpes Simplex Virus Type 2 (HSV-2). 2. Sensitivity: 2ng/ml; accuracy: 99%; 3. Test results can be read visually without any instrument; Features HBsAg Test Procedure 1. No additional instrument or reagent is needed. EASY TO USE; 2. Specifi cation: 96% Sensitive: 95.2%; Strip Cassette 3. Both 5-in-1 test panels and single test cassettes are available. 1 1 Ordering information CAT. NO. Description Method Packing Specimen 120 TORCH 121M TORCH IgM Rapid Screening Test GICA 20 Tests/Box; 33 Boxes/Carton Serum/Plasma 10-20min 2 10-20min TORCH 121G TORCH IgG Rapid Screening Test GICA 20 Tests/Box; 33 Boxes/Carton Serum/Plasma 2 CMV 123M Cytomegalovirus IgM Test GICA/DGFIA** 25 Tests/Box; 40 Boxes/Carton Serum/Plasma 3 3 CMV 123G Cytomegalovirus IgG Test GICA/DGFIA** 25 Tests/Box; 40 Boxes/Carton Serum/Plasma Positive HSV1 125M HSV-1 IgM Test GICA/DGFIA** 25 Tests/Box; 40 Boxes/Carton Serum/Plasma Positive HSV1 125G HSV-1 IgG Test GICA/DGFIA** 25 Tests/Box; 40 Boxes/Carton Serum/Plasma Negative HSV2 126M HSV-2 IgM Test GICA/DGFIA** 25 Tests/Box; 40 Boxes/Carton Serum/Plasma HSV2 126G HSV-2 IgG Test GICA/DGFIA** 25 Tests/Box; 40 Boxes/Carton Serum/Plasma Negative RV 124M Rubella IgM Test GICA/DGFIA** 25 Tests/Box; 40 Boxes/Carton Serum/Plasma Ordering information RV 124G Rubella IgG Test GICA/DGFIA** 25 Tests/Box; 40 Boxes/Carton Serum/Plasma TOXO 122M Toxoplasma IgM Test GICA/DGFIA** 25 Tests/Box; 40 Boxes/Carton Serum/Plasma CAT.
Load more

Recommended publications
  • Dengue–COVID-19 Coinfection: the First Reported Case in the Philippines
    Case Report/Case Series Dengue–COVID-19 coinfection: the first reported case in the Philippines Angyap Saipen,a Bernard Demot,a Lowella De Leona Correspondence to Angyap Lyn Saipen (email: [email protected]) The rainy season in the Philippines is from June to October; this is when the number of dengue cases typically increases. In 2020 during this time, the world was facing the threat of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) infection. Coronavirus disease 2019 (COVID-19) and dengue viral infections have similar presentations and laboratory findings, including fever and thrombocytopenia, and there have been reports of coinfection with SARS-CoV-2 and arthropod-borne virus. Here, we report a case of SARS-CoV-2–dengue virus coinfection in the Philippines in a female aged 62 years, whose early symptom was fever and who was positive for SARS-CoV-2 and positive for dengue. Early recognition of such coinfection is important so that proper measures can be taken in the management of the patient. engue fever is a mosquito-borne viral infection fever (highest recorded at 39.5 °C), with associated found mostly in tropical climates, including headache (frontoparietal in location, rated 5/10 and Dthe Philippines. The clinical manifestations of bandlike in character) and retro-orbital pain, general- dengue may include high-grade fever, headache, retro- ized body ache, myalgia and arthralgia. There was no orbital pain, muscle and joint pains, and rashes. In associated nausea, vomiting or blurring of vision. The 2019, the Philippines had one of the highest numbers patient had pain over the ankle joints, with no associ- of reported dengue cases among countries in Asia ated warmth or limitation of movement, and no rashes, and South-East Asia.1 According to the World Health cough or dyspnoea.
    [Show full text]
  • VDL Annual Report
    2010 Annual Report Table of Contents ISU VDL Mission Statement .......................................................................................................................... 3 VDPAM Organizational Chart ....................................................................................................................... 4 VDPAM External Advisory Board .................................................................................................................. 5 VDL Faculty List ............................................................................................................................................ 6 VDL Staff List ................................................................................................................................................ 7 New Tests Introduced ................................................................................................................................... 9 2010 Statistical Data ................................................................................................................................... 10 Accessions .............................................................................................................................................. 10 Tests ....................................................................................................................................................... 11 Submission Trends ................................................................................................................................
    [Show full text]
  • 69292/2020/Estt-Ne Hr 5
    5 69292/2020/ESTT-NE_HR Index Sr. No. Particulars Page No. 1 General Billing Rules 2--11 2 Packages Detail 12--23 3 Room Rent 24--25 4 Consultation Charges. 26--32 5 CTVS PACKAGE ROCEDURES 33--35 6 CTVS PEDIATRIC 36--37 7 CATH ADULT PROCEDURES 38--39 8 EP STUDY PACKAGE PROCEDURES 40--41 9 PEDIATRIC CATH PROCEDURES 42--43 10 UROLOGY PROCEDURES 44--46 11 NEPHROLOGY PROCEDURES 47-52 12 VASCULAR SURGERY 53--54 13 GENERAL SURGERY PROCEDURE 55--62 14 NUEROLOGY PROCEDURES 63--67 15 UROLOGY 68--71 16 DENTAL PROCEDURES 72--78 17 DERMATALOGY PROCEDURES 79--82 18 ENT PROCEDURES 83--87 19 NEPHROLOGY 88--89 20 GYNECOLOGY PROCEDURES 90--93 21 LABORATORY TEST CHARGES 94-120 22 ONCOLOGY PROCEDURES 121-126 23 OPTHALMOLOGY PROCEDURES 127-130 24 PULMONOLOGY PROCEDURES 131-134 25 PAIN CLINIC CHARGES 135-136 26 PLASTIC SURGERY 137-141 27 PHYSIOTHERAPY CHARGES 142-144 28 MISC. & OTHER SERVICES 145-148 29 CARDIAC DIAGNOSTIC CHARGES 149-151 30 CT PROCEDURES 152-155 31 MRI PROCEDURES 156-162 32 X RAY PROCEDURES 163-166 33 ULTRASOUND PROCEDURES 167-169 34 DIAGNOSTIC NEUROLOGY 170-172 35 DIANG-HIS 173-174 36 BLOOD BANK 175-176 37 GASTROENTEROLOGY PACKAGES 177-178 38 GASTROENTEROLOGY 179-184 39 TRANSPLANT CHARGES 185-186 0 6 69292/2020/ESTT-NE_HR 40 ORTHOPAEDIC PACKAGES 187-189 41 ORTHOPAEDICS PROCEDURES 190-199 42 MAXILLOFACIAL SURGERY 200-206 43 ONCO SURGERY 207-209 44 INTERVENTIONAL RADIOLOGY & CARDIOLOGY 210-211 45 ANESTHESIA PROCEDURES 212-214 46 PSYCHOLOGY 215-216 1 7 69292/2020/ESTT-NE_HR GENERAL BILLING RULES & GUIDELINES 2 8 69292/2020/ESTT-NE_HR Registration and Admission Charges a) Onetime Registration charges of INR.100/- shall be charged to all new patients coming to Hospital for the first time.
    [Show full text]
  • Severe Dengue Due to Secondary Hemophagocytic Lymphohistiocytosis
    IDCases 8 (2017) 50–53 Contents lists available at ScienceDirect IDCases journal homepage: www.elsevier.com/locate/idcr Case report Severe dengue due to secondary hemophagocytic lymphohistiocytosis: A case study Ujjwayini Ray*, Soma Dutta, Susovan Mondal, Syamasis Bandyopadhyay Apollo Gleneagles Hospitals, 58, Canal Circular Road, Kolkata 70054, West Bengal, India A R T I C L E I N F O A B S T R A C T Article history: Received 17 March 2017 Dengue, transmitted by the mosquito Aedes aegypti affects millions of people worldwide every year. Received in revised form 25 March 2017 Dengue induced hemophagocytic lymphohistiocytosis (HLH) is a serious condition and may prove fatal if Accepted 25 March 2017 not detected early and treated appropriately. Diagnosis of HLH is challenging and usually missed as Available online xxx clinical and laboratory findings are nonspecific. Moreover, the pathophysiology of the systemic inflammatory response syndrome and/or sepsis is remarkably similar to HLH. Secondary HLH following Keywords: infection by the dengue virus is now being increasingly recognized as a cause of severe form of the Bicytopenia disease. We report a case of dengue associated HLH in an otherwise healthy person who deteriorated Dengue during the course of hospitalization. A disproportionately high ferritin level and persistent bicytopenia Hemophagocytic lymphohistiocytosis prompted investigations for HLH. Diagnosis of dengue fever with virus-associated hemophagocytic (HLH) Infection syndrome was established according to the diagnostic criteria laid down by the Histiocyte Society. We discuss the diagnosis and management of this complex case and try to generate awareness about dengue Intravenous immunoglobulin G induced HLH as one of the possible causes for severe manifestations of this infection © 2017 The Authors.
    [Show full text]
  • Flavivirus Cross-Reactivity to Dengue Nonstructural Protein 1 Antigen Detection Assays
    diagnostics Article Flavivirus Cross-Reactivity to Dengue Nonstructural Protein 1 Antigen Detection Assays Li Kiang Tan 1, Wing Yan Wong 1, Hui Ting Yang 1, Roland G. Huber 2 , Peter J. Bond 2,3, Lee Ching Ng 1,4, Sebastian Maurer-Stroh 2,3 and Hapuarachchige Chanditha Hapuarachchi 1,* 1 Environmental Health Institute, National Environment Agency, Singapore 38667, Singapore; [email protected] (L.K.T.); [email protected] (W.Y.W.); [email protected] (H.T.Y.); [email protected] (L.C.N.) 2 Bioinformatics Institute, Agency for Science, Technology and Research, Singapore 138671, Singapore; [email protected] (R.G.H.); [email protected] (P.J.B.); [email protected] (S.M.-S.) 3 Department of Biological Sciences, National University of Singapore, Singapore 117558, Singapore 4 School of Biological Sciences, Nanyang Technological University, Singapore 639798, Singapore * Correspondence: [email protected]; Tel.: +65-65115335; Fax: +65-65115339 Received: 7 November 2019; Accepted: 23 December 2019; Published: 24 December 2019 Abstract: Dengue virus (DENV) and Zika virus (ZIKV) are flaviviruses of public health relevance. Both viruses circulate in the same endemic settings and acute infections generally manifest similar symptoms. This highlights the importance of accurate diagnosis for clinical management and outbreak control. One of the commonly used acute diagnostic markers for flaviviruses is nonstructural protein 1 (NS1). However, false positives due to antigenic cross-reactivity have been reported between DENV and ZIKV infections when using DENV NS1 antigen (NS1 Ag) detection assays in acute cases. Therefore, we investigated the lowest detectable virus titres and cross-reactivity of three commercial dengue NS1 Ag rapid assays and two ELISAs for different flaviviruses.
    [Show full text]
  • Detection of NS1 Antigen in Serologically Confirmed Dengue Cases at Least After 5 Days of Infection
    Research Article Anatomy Physiol Biochem Int J Volume 4 Issue 2- February 2018 Copyright © All rights are reserved by Sudipta Poddar DOI: 10.19080/APBIJ.2017.04.555632 Detection of NS1 Antigen in Serologically Confirmed Dengue Cases at least after 5 Days of Infection Sudipta Poddar* and Amiya Kumar Hati Department of Medical Physiology, Lincoln University College, Malaysia Submission: January 01, 2017; Published: February 09, 2018 *Corresponding author: Sudipta Poddar, Department of Medical Physiology, Lincoln University College, 47301, Petaling Jaya, Malaysia; Email: Abstract Objectives: The objective of this paper is to detect the NS1 antigen beyond 5 days of infection in serologically confirmed dengue cases in whom both NS1 antigen and IgG and IgM antibodies were assessed. Methods: Out of a total of 1037 suspected persons 257 i.e. 24.78% were dengue reactive in 2013 and 2014. Dengue cases were diagnosed in the laboratory from suspected patients by dengue specific IgG, IgM antibodies and NS1 antigen. NS1 antigen and IgG antibodies were monitored in 220 (194+26) suspected dengue cases where interpretation was possible to detect NS1 beyond 5 days of infection. This study of detection of NS1 antigen in serologically confirmed dengue cases at least after 5 days of infection. Results: Among this 220 cases 86 (80+6) were confirmed dengue cases. Out of these 86 cases NS1 antigen was found beyond 5 days of infection in 15 i.e. 17.44%. Conclusion: It would be reasonable to believe that many such cases would be found in the category I where only NS1 was tested. Hence for getting the information on NS1 antigen beyond 5 days all three serological tests (NS1 antigen, IgG and IgM antibodies) should be performed.
    [Show full text]
  • The Point-Of-Care Diagnostic Landscape for Sexually Transmitted Infections (Stis)
    The Point-of-Care Diagnostic Landscape for Sexually Transmitted Infections (STIs) Maurine M. Murtagh The Murtagh Group, LLC 2019 1 Introduction Sexually transmitted infections (STIs) continue to be a significant global public health issue, with an estimated 378 million people becoming ill in 2016 with one of 4 STIs: syphilis, Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) (1) . In addition, more than 291 million women have a human papillomavirus (HPV) infection, which is a necessary cause of high grade cervical intraepithelial neoplasia (grade 2 or higher [CIN2+]) (1). This report considers the available and pipeline diagnostics for curable STIs, namely syphilis, CT, NG, TV, and HPV. With some exceptions, the existing diagnostics for these STIs are laboratory-based platforms, which typically require strong infrastructure and well-trained laboratory technicians. In addition, test turnaround time (TAT) is often long, requiring patients to return for test results on a subsequent clinic visit. This, in turn, leads to significant loss to follow-up. Therefore, while these laboratory-based diagnostics are effective, they may not always be suitable for use in resource-limited settings where diagnostic access and delivery are difficult. There are now a variety of tests available for use at or near the point of patient care (POC) for STIs (2). These include a wide range of rapid diagnostic tests (RDTs) for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and syphilis, among others, with which it is possible to detect infection using fingerprick blood, or in some cases, oral fluid.1 In addition, other types of POC tests, including simple molecular tests for use in primary healthcare settings, have also become available recently.
    [Show full text]
  • The Point-Of-Care Diagnostic Landscape for Sexually Transmitted Infections (Stis)
    The Point-of-Care Diagnostic Landscape for Sexually Transmitted Infections (STIs) Maurine M. Murtagh The Murtagh Group, LLC 31 May 2018 1 Sexually transmitted infections (STIs) continue to be a significant global public health issue, with an estimated 357 million people becoming ill each year with one of 4 STIs: syphilis, Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) (1). In addition, more than 290 million women have a human papillomavirus (HPV), which infection is a necessary cause of high grade cervical intraepithelial neoplasia (grade 2 or higher [CIN2+]) (1). This report considers the available and pipeline diagnostics for curable STIs, namely syphilis, CT, NG, TV, and HPV. With some exceptions, the existing diagnostics for these STIs are laboratory-based platforms, which typically require strong laboratory infrastructure and well-trained laboratory technicians. In addition, test turnaround time is often long, requiring patients to return for test results on a subsequent clinic visit. This, in turn, leads to significant loss to follow-up. Therefore, while these laboratory-based diagnostics are effective, they may not always be suitable for use in resource-limited settings where diagnostic access and delivery are difficult. There are now a variety of tests available for use at or near the point of patient care (POC) for STIs (2). These include a wide range of rapid diagnostic tests (RDTs) for human immunodeficiency virus (HIV), hepatitis C virus and syphilis, among others, with which it is possible to detect infection using fingerprick blood, or in some cases, oral fluid.1 In addition, other types of POC tests, including simple molecular tests for use in primary healthcare settings, have also become available recently.
    [Show full text]
  • Design and Development of Small Molecule Based Biosensors for Detection of Pathogens
    Georgia State University ScholarWorks @ Georgia State University Chemistry Dissertations Department of Chemistry Fall 12-3-2018 Design and development of small molecule based biosensors for detection of pathogens Amrita Das Amrita Das Follow this and additional works at: https://scholarworks.gsu.edu/chemistry_diss Recommended Citation Das, Amrita, "Design and development of small molecule based biosensors for detection of pathogens." Dissertation, Georgia State University, 2018. https://scholarworks.gsu.edu/chemistry_diss/159 This Dissertation is brought to you for free and open access by the Department of Chemistry at ScholarWorks @ Georgia State University. It has been accepted for inclusion in Chemistry Dissertations by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please contact [email protected]. i DESIGN AND DEVELOPMENT OF SMALL MOLECULE BASED BIOSENSORS FOR DETECTION OF PATHOGENS by AMRITA DAS Under the Direction of Suri S Iyer. Ph.D. i ii ABSTRACT Glycans are present on the cell surface of mammalian cells. In Dr. Iyer’s laboratories, we aim to understand the interactions of cell surface glycans with toxins and pathogens at a molecular level and use that information to develop a point of care diagnostics. This thesis primarily focuses on the development of new technologies that could potentially be further developed towards the point of care diagnostics. Chapter 1, the introduction chapter focuses on the biosensors, different recognition molecules, various reporters, techniques, testing parameters used in biosensors and point of care testing (POCT). In chapter 2, the focus is on the development of a novel electrochemical assay that uses repurposed glucose meters for the detection of different analytes.
    [Show full text]
  • Brochure Design 2020 04 15 V2
    D I S C O V E R Rapid Assays Rapid Reliable Expedient T E S T, D I A G N O S E & T R E A T RAPI DAS SAYS ImmunoScience India Pvt. Ltd. Gat No. 41, Village Kusgaon, Shivapur-Velhe Road, Taluka: Bhor, Pune 412205 Maharashtra, India An ISO 9001:2015 and ISO 13485:2016 Company [email protected] OUR NEWEST ADDITION ImmunoQuick Covid-19 IgM/IgG Rapid test for the detection of IgM and IgG antibodies in serum or plasma. Tested by National Institute of Virology, Pune. ImmunoQuick One StepPregnancy Pregnancy Test Device / Dipstick Intended Use : ImmunoQuick Pregnancy, est Pregnancy evice immunoassay for the rapid and visual determination of hCG (human Chorionic D O p Pregnancy T Pregnancy p n e te S te p S ne P D O r e e Pregnancy vic g Gonadotropin) hormone in human urine specimen to aid in the early detection of n e a n c y T e s t pregnancy. Two Formats ISO 9001 : 2015 ISO 13485 : 2016 } Certified Company est 25 One Step Procedure - T cy Pregnancy regnan Dipstick O n Fast - e P tep S - Device (Cassette) and Dipstick (Strip) te p S ne P D O ip r e Pregnancy s g tic n a k n c Duration - Result as early as 30 Seconds y T e One step pregnancy test is a self testing st Clear Results - 5 minutes Easy to use, ISO 9001 : 2015 } Certified Company ISO 13485 : 2016 Early detection - 25 High Sensitivity - Easy to interpret with clear test andSample dark control dropper bands provided with device format.
    [Show full text]
  • Dengue–COVID-19 Coinfection
    COVID-19: Case Report/SeriesArticle type Dengue–COVID-19 coinfection: the first reported case in the Philippines Angyap Saipen,a Bernard Demot,a Lowella De Leona Correspondence to Angyap Lyn Saipen (email: [email protected]) The rainy season in the Philippines is from June to October; this is when the number of dengue cases typically increases. In 2020 during this time, the world was facing the threat of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) infection. Coronavirus disease 2019 (COVID-19) and dengue viral infections have similar presentations and laboratory findings, including fever and thrombocytopenia, and there have been reports of coinfection with SARS-CoV-2 and arthropod-borne virus. Here, we report a case of SARS-CoV-2–dengue virus coinfection in the Philippines in a female aged 62 years, whose early symptom was fever and who was positive for SARS-CoV-2 and positive for dengue. Early recognition of such coinfection is important so that proper measures can be taken in the management of the patient. engue fever is a mosquito-borne viral infection fever (highest recorded at 39.5 °C), with associated found mostly in tropical climates, including headache (frontoparietal in location, rated 5/10 and Dthe Philippines. The clinical manifestations of bandlike in character) and retro-orbital pain, general- dengue may include high-grade fever, headache, retro- ized body ache, myalgia and arthralgia. There was no orbital pain, muscle and joint pains, and rashes. In associated nausea, vomiting or blurring of vision. The 2019, the Philippines had one of the highest numbers patient had pain over the ankle joints, with no associ- of reported dengue cases among countries in Asia ated warmth or limitation of movement, and no rashes, and South-East Asia.1 According to the World Health cough or dyspnoea.
    [Show full text]
  • Sd Product Catalog
    SD PRODUCT CATALOG Ordering When you place an order, please inform us of full description, product catalog number, unit size, quantity required including any special instructions with the correct billing and shipping address. Please note that individual products may have different specifications in various markets. Also, some products may not be available in all markets worldwide, only in selected markets. Standard Diagnostics, Inc. 65, Borahagal-ro, Giheung-gu, Yongin-si, Gyeonggi-do, Republic of Korea Tel No. : +82-31-899-2800 Fax No. : +82-31-899-2840 E-Mail : [email protected] Cancellation Any order cancellation should be informed to us within 2 days after placing purchase order. Special custom or large volume orders can not be cancelled at our sole discretion. Pricing Prices will be quoted upon request in US Dollars and are subject to change without prior notice. Quantity discounts are available for bulk. Payment Terms All orders are prepaid unless prior credit arrangements have been made with our Finance Department. All orders are F.O.B. from our factory. Freight charges and insurance charges are the responsibility of the customer. Prices are subject to change without prior notice. Shipping Shipments are made on FCA basis unless otherwise specified. The cost of courier service and special handling if requested shall be the customer’s responsibility. Please specify your shipping requirements when placing your order. Returned Goods Policy No returns shall be accepted without prior approval from SD in the form of an assigned Return Goods Authorization (RGA) Number. To return unused products in error sent to you, please contact us for a RGA Number and further details.
    [Show full text]